Methods and Systems for Modifying Empathy by Modulating Type 2 Theta Oscillations

Patent metadata

Field	Value
Publication number	US-2023364423-A1
Application number	US-202118027023-A
Country	US
Kind code	A1
Filing date	Sep 30, 2021
Priority date	Oct 1, 2020
Publication date	Nov 16, 2023
Grant date	—

Abstract

The disclosure pertains to methods for modifying empathy in a subject, such as a human, by modulating type 2 theta oscillations in a brain region of the subject. The methods include increasing empathy in a subject, such as a human, by increasing type 2 theta oscillations in a brain region of the subject, thereby increasing empathy in the subject. The human subject may have a psychiatric or neurological condition that causes suboptimal empathy. Modulating type 2 theta oscillations in a brain region of a subject can be accomplished by optogenetic treatment, electric stimulation of a brain region, administration of a pharmaceutical drug, or a combination thereof. Also provided are systems for performing the methods disclosed herein.

First claim

We claim:

1 . A method of modulating empathy in a human, comprising: modulating type 2 theta oscillations in a brain region of the human.

2 . The method of claim 1 , wherein modulating empathy comprises increasing empathy in the human, wherein the human has suboptimal empathy.

3 . The method of claim 2 , wherein the suboptimal empathy in the human is caused by a psychiatric or neurological condition.

4 . The method of any of preceding claims, wherein modulating type 2 theta oscillations comprises optogenetic treatment with or without entrainment.

5 . The method of claim 4 , wherein the optogenetic treatment comprises stimulating GABAergic neurons.

6 . The method of claim 5 , wherein the GABAergic neurons are located at the fimbria fornix.

7 . The method of claim 5 , wherein the GABAergic neurons are located at the septo-hippocampus.

8 . The method of any of claims 1 to 3 , wherein modulating type 2 theta oscillations comprises genetically modifying neurons in the brain region to directly modulate type-2 theta oscillations.

9 . The method claim 8 , wherein genetically modifying neurons in the brain region comprises modifying the expression of one or more genes encoding Ca v 3.2, Ca v 3.1, CAV3, PLC-β1, and PLC-β4.

10 . The method of any of claims 1 to 3 , wherein modulating type 2 theta oscillations comprises electrical stimulation of the brain region using one or more electrodes.

11 . The method of any of claims 1 to 3 , wherein the modulating comprises administering to the human a pharmaceutical drug.

12 . The method of claim 11 , wherein the pharmaceutical drug is an anticholinesterase agent.

13 . The method of claim 12 , wherein the anticholinesterase agent is atropine or physostigmine.

14 . The method of claim 11 , wherein the pharmaceutical drug is an activator of PLC.

15 . The method of claim 14 , wherein the activator of PLC is an activator of PLC-β1 and/or PLC-β4.

16 . The method of claim 14 or 15 , wherein the activator of PLC is m3M3FBS (2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfonamide) or thapsigargin.

17 . The method of any of claims 1 to 3 , wherein the brain region is: hippocampus, septo-hippocampus, anterior cingulate cortex (ACC), basolateral amygdala (BLA), midline thalamus, insulate regions, medial septum (MS), or fimbria fornix.

18 . The method of any of claims 1 to 3 , wherein the type 2 theta oscillations are synchronized in the hippocampus, ACC, or BLA.

19 . The method of claim 3 , wherein the psychiatric or neurological condition is: Alzheimer's disease, autism spectrum disorder, dementia, addiction, depression, anxiety, bipolar disorder, schizophrenia, attention-deficit hyperactivity disorder (ADHD), alexithymia, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), psychopathy, Parkinson's disease, or epilepsy.

20 . The method of claim 19 , wherein the psychiatric or neurological condition is selected from the group consisting of: autism spectrum disorder, dementia, and addiction.

21 . The method of any of claims 1 to 3 , wherein the modulating is increasing type 2 theta oscillations.

22 . The method of claim 1 , wherein the modulating is decreasing type 2 theta oscillations.

23 . The method of any of claims 1 to 3 , wherein the modulating of type 2 theta oscillations does not induce modulation of type 1 theta oscillations.

24 . A system for modulating empathy in a human, comprising: a device configured to modulate type 2 theta oscillations in a brain region of the human.

25 . The system of claim 24 , wherein the device is configured to increase empathy in a human having suboptimal empathy.

26 . The system of claim 24 or 25 , wherein the device is an optogenetic device comprising a light source operationally coupled to a light transmitter configured and positioned to deliver light to the brain region.

27 . The system of claim 24 or 25 , wherein the device is an electrical stimulation device comprising an electrical current generator operationally coupled to at least one electrode configured and positioned to deliver electrical stimulation to the brain region.

28 . The system of claim 27 , wherein the system comprises two electrodes.

29 . The system of claim 24 or 25 , wherein the brain region is: hippocampus, septo-hippocampus, ACC, BLA, midline thalamus, insulate regions, medial septum, fimbria fornix, amygdala, or a combination thereof.

Assignees

• The Board Of Trustees Of Leland Stanford Junior Univ
• Inst Basic Science

Inventors

• Lee Jin Hyung
• Shin Hee-Sup

Classifications

• C07K14/70571

  for neuromediators, e.g. serotonin receptor, dopamine receptor · CPC title

• C12Y301/04003

  Phospholipase C (3.1.4.3) · CPC title

• A01K2267/0356

  Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy · CPC title

• A01K2217/206

  Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase · CPC title

• A01K2217/15

  Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding · CPC title